Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Orth, S. R.
Right arrow Articles by Ritz, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Orth, S. R.
Right arrow Articles by Ritz, E.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2003) 18: 62-69
© 2003 European Renal Association-European Dialysis and Transplant Association

Combination treatment with an ETA-receptor blocker and an ACE inhibitor is not superior to the respective monotherapies in attenuating chronic transplant vasculopathy in different aorta allotransplantation rat models

Stephan R. Orth1,, Giulio Odoni2, Henryk Karkoszka2, Hiroaki Ogata2, Christiane Viedt2, Kerstin Amann3, Paolo Ferrari1 and Eberhard Ritz2

1 Division of Nephrology and Hypertension, University Hospital Berne (Inselspital), Berne, Switzerland, 2 Department of Internal Medicine, Ruperto Carola University, Heidelberg and 3 Department of Pathology, University Erlangen-Nürnberg, Germany

Background. The effect of the specific endothelin A (ETA)-receptor antagonist LU 302146 (LU) was assessed in a normotensive model of chronic transplant vasculopathy, i.e. orthotopic allotransplantation of the infrarenal abdominal aorta from spontaneously hypertensive-to-Wistar–Kyoto (SHR-to-WKY) rats. A second experimental setting was used to confirm the results in a different model, which to some extent may also address the issue of blood pressure (BP) in transplant vasculopathy, i.e. orthotopic allotransplantation of infrarenal abdominal aorta from WKY-to-SHR rats. Untreated sham-operated and isografted WKY and SHR served as controls. Allotransplanted animals treated with the angiotensin-converting enzyme (ACE) inhibitor trandolapril served as positive treatment controls.

Methods. Rats were randomized to receive standard diet or a diet designed to deliver either 30 mg LU/kg bw/day, 0.3 mg/kg bw/day trandolapril or a combination of both. The duration of either experiment was 8 weeks. BP was measured by tail plethysmography.

Results. Treatment with LU did not affect systolic BP in either experimental setting. In contrast, trandolapril and combination treatment significantly reduced systolic BP in SHRs. The increase in aortic wall thickness (given in mm) was abrogated to a similar extent in the three treatment groups as compared with untreated allotransplanted animals in either experimental setting (e.g. WKY sham-operated 0.084±0.013, P<0.05 vs treatment groups; WKY isotransplanted 0.100±0.010, P<0.05 vs treatment groups; WKY allotransplanted 0.289±0.077, P<0.05 vs all groups; WKY allotransplanted+trandolapril 0.185±0.025; WKY allotransplanted+LU 301246 0.192±0.049; WKY allotransplanted+LU 301246+trandolapril 0.190±0.041). This was due to an attenuation of the increase of intima and media thickness. Treatment with LU and trandolapril were similarly effective in attenuating the increase of the number of proliferating cell nuclear antigen (PCNA)-positive cells in the intima. Again, combination treatment did not confer additional benefit. In contrast, trandolapril was more effective than LU in attenuating the increase in the number of PCNA-positive cells in the media. Trandolapril or combination treatment, but not LU, attenuated transforming growth factor-ß expression in aortic allografts.

Conclusions. The ETA-receptor blockade abrogates allograft vasculopathy in two different aorta allotransplantation models to a similar extent as ACE inhibition even in the absence of concomitant immunosuppression. At least in SHRs the effect of ETA-receptor blockade is independent of BP. This finding is consistent with the notion that ETA-receptor mediated events play a partly BP-independent role in the genesis of chronic transplant vasculopathy.

Keywords: ACE inhibitor; chronic allograft vasculopathy; endothelin; endothelin antagonist; endothelin receptor

Correspondence and offprint requests to: Stephan R. Orth, MD, Division of Nephrology and Hypertension, University Hospital Berne (Inselspital), Freiburgstrasse 10, CH-3010 Berne, Switzerland. Email: stephan.orth{at}insel.ch


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Exp. Biol. Med.Home page
B. Battistini, N. Berthiaume, N. F. Kelland, D. J. Webb, and D. E. Kohan
Profile of Past and Current Clinical Trials Involving Endothelin Receptor Antagonists: The Novel "-Sentan" Class of Drug.
Experimental Biology and Medicine, June 1, 2006; 231(6): 653 - 695.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
K. Frank, M. Zeier, M.-L. Gross, R. Waldherr, E. Ritz, and K. Amann
Comprehensive immunohistological analysis of the endothelin system in human kidney grafts
Nephrol. Dial. Transplant., May 1, 2006; 21(5): 1365 - 1372.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.